Shots:

• The approval is granted in pediatric plaque psoriasis and non-infectious intermediate uveitis- posterior uveitis and panuveitis in adults- who do not respond adequately to corticosteroids.
• These are fifth and sixth approved indications of Sulinno in China and it was first approved by NMPA on Sep 2- 2020
• Sulinno is an adalimumab biosimilar which is a recombinant human anti-TNF-α mAB developed by Innovent and are indicated in rheumatoid arthritis- ankylosing spondylitis- psoriasis- and polyarticular juvenile idiopathic arthritis.

 ­ Ref: Innovent  | Image: Innovent